Domestic Breakthrough Infection Rate 0.074%... Janssen-AZ-Pfizer-Moderna Order

On the 12th, at the Central Vaccination Center of the National Medical Center in Jung-gu, Seoul, healthcare workers at COVID-19 treatment hospitals, who are six months past their primary vaccination, are having their temperatures checked before receiving their additional booster shots. Photo by Kim Hyun-min kimhyun81@

[Asia Economy Reporter Seo So-jeong] Among the 26,938,731 people who have completed COVID-19 vaccination in South Korea, 19,954 cases have been identified as 'breakthrough infections.'

The Central Disease Control Headquarters announced on the 27th that the cumulative breakthrough infection rate in the country is 0.074% (as of the 17th), estimating that 74.1 out of every 100,000 vaccinated individuals experienced breakthrough infections.

According to the monthly breakthrough infection status, the number of breakthrough infections, which was only 2 in April, increased to 8,911 last month. As of the 17th of this month, 6,974 cases were identified as breakthrough infections.

By age group, the incidence rate was highest among those in their 30s at 0.134% (134.3 cases per 100,000 vaccinated individuals).

By vaccine type, Janssen had the highest incidence rate at 0.267%, followed by AstraZeneca (0.099%), mixed vaccinations (0.071%), Pfizer (0.048%), and Moderna (0.005%).

Among the estimated breakthrough infection cases, 281 were severe or critical, and 87 resulted in death.

Additionally, among 4,117 cases where variant virus analysis was completed, major variants were confirmed in 3,888 cases (94.4%). The Delta variant accounted for the majority with 3,855 cases, followed by Alpha (30 cases), Gamma (2 cases), and Beta (1 case).